Abstract: In one example in accordance with the present disclosure, a fluid ejection device component is described. The example fluid ejection device component includes a fluidic structure (100) with at least one channel to deliver fluid to a fluid ejection die and at least one via for passing electrical routing.

Abstract: In one example in accordance with the present disclosure, a fluid ejection device assembly is described. The fluid ejection device assembly includes a monolithically molded fluidic structure to extend between a separately molded body comprising a print fluid reservoir and a fluid ejection device. The fluidic structure includes a plenum to receive a print fluid from the body at a fluidic interface.

Abstract: The invention is in the field of delivery of transgenes to target cells using viral vectors, particularly in the field of gene therapy. Compositions have been identified which allow for oral administration of viral particles, particularly adenoviral particles.

Abstract: The invention is in the field of delivery of transgenes to target cells using viral vectors, particularly in the field of gene therapy. Compositions have been identified which allow for oral administration of viral particles, particularly adenoviral particles.

Abstract: The disclosure relates to the production of viral particles, in particular adenoviral particles for use in vaccines. Modified chimeric coronavirus spike antigens are disclosed, together with polynucleotides encoding said antigens, viral particles and methods of production/formulation of the viral particles.

Abstract: Systems and methods for managing tasks in a multi-platform environment are provided. The methods include allocating a set of tasks to a server device; receiving a request for servicing one or more tasks; determining whether rules that are applicable to the tasks have been satisfied; and, based on the determination regarding the rules, either automatically servicing the tasks or transmitting the tasks to the server device for servicing and then receiving a notification of completion of the tasks. Additional tasks may be allocated to additional server devices.

Abstract: The invention relates to an immunogenic composition comprising influenza virus antigens derived from at least 5 influenza virus strains and one or more compounds of formula (I) or physiologically acceptable salts or esters thereof: wherein: R1 represents hydrogen or C1-6 alkyl; R2 represents C1-6 alkyl; and R3 represents C1-6 alkyl. The invention also relates to methods of preparing the immunogenic composition, to pharmaceutical and vaccine compositions comprising the immunogenic composition and to use of the immunogenic, pharmaceutical and vaccine compositions for preventing influenza virus infection.

Abstract: The present invention relates to the use of an excipient which is a compound of formula (I) or a physiologically acceptable salt or ester thereof: wherein: R1 represents C1-6alkyl; R2 represents hydrogen or C1-6alkyl; and R3 represents C1-6alkyl, for increasing the immunogenicity of an influenza antigen, which use comprises (a) freezing, (b) heat-treating, and/or (c) freeze-drying an aqueous composition comprising the influenza antigen and the excipient.

Abstract: A sterile pharmaceutically acceptable aqueous solution, which solution is provided in a sealed container and comprises: a pharmaceutically acceptable aqueous solvent; viral particles or a physiologically active polypeptide; an excipient selected from a polyethyleneimine; a compound of formula (I) or a physiologically acceptable salt or ester thereof; or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and optionally, one or more sugars.

Abstract: The invention relates to an immunogenic composition comprising influenza virus antigens derived from at least 5 influenza virus strains and one or more compounds of formula (I) or physiologically acceptable salts or esters thereof: wherein: R1 represents hydrogen or C1-6 alkyl; R2 represents C1-6 alkyl; and R3 represents C1-6 alkyl. The invention also relates to methods of preparing the immunogenic composition, to pharmaceutical and vaccine compositions comprising the immunogenic composition and to use of the immunogenic, pharmaceutical and vaccine compositions for preventing influenza virus infection.

Abstract: Systems and methods for managing tasks in a multi-platform environment are provided. The methods include allocating a set of tasks to a server device; receiving a request for servicing one or more tasks; determining whether rules that are applicable to the tasks have been satisfied; and, based on the determination regarding the rules, either automatically servicing the tasks or transmitting the tasks to the server device for servicing and then receiving a notification of completion of the tasks. Additional tasks may be allocated to additional server devices.

Abstract: The invention is in the field of delivery of transgenes to target cells using viral vectors, particularly in the field of gene therapy. Compositions have been identified which allow for oral administration of viral particles, particularly adenoviral particles.

Abstract: A method for preserving viral particles comprising: (a) providing an aqueous solution of (i) viral particles, (ii) optionally one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating said viral particles.

Abstract: The present invention relates to the use of a combination of: (i) a macromolecular erythrocyte sedimentation enhancer, and (ii) dimethyl sulphoxide (DMSO), dimethylglycine (DMG) and/or valine; to recover non-erythrocyte blood cells from a blood cell-containing sample and/or to prime non-erythrocyte blood cells to protect their integrity in subsequent cryopreservation step(s).

Abstract: A method for preserving a polypeptide comprising: (a) providing an aqueous solution of (i) the polypeptide, (ii) one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating the polypeptide.

Abstract: A method for preserving viral particles comprising: (a) providing an aqueous solution of (i) viral particles, (ii) optionally one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating said viral particles.

Abstract: The present invention relates to the use of a combination of: (i)a macromolecular erythrocyte sedimentation enhancer, and (ii) dimethyl sulphoxide (DMSO), dimethylglycine (DMG) and/or valine; to recover non-erythrocyte blood cells from a blood cell-containing sample and/or to prime non-erythrocyte blood cells to protect their integrity in subsequent cryopreservation step(s).

Abstract: The present invention relates to the use of an excipient which is a compound of formula (I) or a physiologically acceptable salt or ester thereof: wherein: R1 represents C1-6alkyl; R2 represents hydrogen or C1-6alkyl; and R3 represents C1-6alkyl, for increasing the immunogenicity of an influenza antigen, which use comprises (a) freezing, (b) heat-treating, and/or (c) freeze-drying an aqueous composition comprising the influenza antigen and the excipient.

Abstract: The present invention relates to the use of an excipient which is a compound of formula (I) or a physiologically acceptable salt or ester thereof: wherein: R1 represents C1-6alkyl; R2 represents hydrogen or C1-6alkyl; and R3 represents C1-6alkyl, for increasing the immunogenicity of an influenza antigen, which use comprises (a) freezing, (b) heat-treating, and/or (c) freeze-drying an aqueous composition comprising the influenza antigen and the excipient.

Abstract: A method for preserving a polypeptide comprising: (a) providing an aqueous solution of (i) the polypeptide, (ii) one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating the polypeptide.